ClinicalTrials.gg

Program

HMGB1 Inhibitor SB17170

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by SPARK Biopharma.

Furthest: phase 2, since Dec 17, 20244 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SPARK Biopharma42 open or runningphase 2since Dec 17, 2024Aug 25, 2022Jun 30, 2027phase 1 · NCT05522868

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2022First study: phase 1 study in Solid TumorFirst studyNCT05522868 · 50 planned · South Korea
  2. Feb 27, 2023Phase 1 study in Safety IssuesNCT05795192 · 64 enrolled · Korea, Republic of
  3. Dec 17, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06747923 · 30 planned · South Korea
  4. Feb 19, 2025Phase 1 study in Drug Drug Interaction (DDI)NCT06846684 · 12 enrolled · South Korea

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in Solid TumorNCT05522868

TargetBeta

HMGB1 →read by rule
“An orally bioavailable prodrug of SB1703, a small molecule inhibitor of high mobility group protein B1 (HMGB1), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06846684Drug Drug Interaction (DDI) · South Korea1CompletedJun 10, 202512
NCT06747923Idiopathic Pulmonary Fibrosis · South Korea2RecruitingMay 30, 202630
NCT05795192Safety Issues · Korea, Republic of1CompletedFeb 29, 202464
NCT05522868Solid Tumor · South Korea1RecruitingJun 30, 202750

How it is read

Names in the registry

  • “SB17170”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.